Introduction. The high frequency of recurrence of chronic bacterial prostatitis may be due to the weakening of local and systemic immunity. This determines the need for immunotropic therapy in this disease. Target. To evaluate the effectiveness of «Tubosan» in the complex therapy of chronic bacterial prostatitis. Materials and methods. A comparative controlled cohort study was conducted. The study included 60 men with a microbiologically confirmed diagnosis of chronic bacterial prostatitis. The main group received antibiotic therapy in combination with «Tubosan». Control - only antibiotic therapy. The duration of treatment in both groups was 28 days. All patients underwent an IPSS questionnaire, microscopy, and culture of prostate secretion. Results and discussion. All patients of both groups showed complete eradication of pathogens according to the results of seeding of the secret of the prostate gland. In patients of the main group, a more pronounced decrease in symptoms was observed compared with the control. The sum of points on the IPSS scale before and after treatment in the main group was 21,9±1.3 vs 8.7±2.2, in the control group - 22.2±10.3 vs 10.3±1.4 points, respectively ( p<0.001). In the main group, there was a more significant decrease in the inflammatory process in the prostate. The average number of leukocytes in the field of view in the main group before and after treatment was 101.0±23.2 vs 5.2±1.3 cells (p<0.001), in the control group 101.6±21.5 vs 16.8±6.2 cells (p<0.001), respectively. After treatment, both groups showed a statistically significant improvement in the quality of life of patients, as assessed by the answer to question 7 of the IPSS questionnaire. In the main group, the average score on question No. 7 before and after treatment was 3.9±0.6 vs 1.8±0.5 points, respectively (p<0.001) 3.9±0.6 points vs 2.3±0.4 points, respectively (p<0.001). Conclusion. «Tubosan» can be used as an immunotropic agent in the complex therapy of chronic bacterial prostatitis to improve treatment outcomes

Introduction. Despite the frequent occurrence of balanoposthitis, due to the wide variety of pathogens, it is often difficult to find an effective therapy. Purpose. To evaluate the extent of changes in complaints during therapy by the complex drug Balanex and its effectiveness. Materials and methods. The study was conducted as a prospective comparative cohort. The study included 120 patients with typical complaints for balanoposthitis. Patients were randomized according to chronic diseases and balanoposthitis therapy. The first group included 59 men with nonspecific balanoposthitis, for whom Balanex cream gel was prescribed topically 2 times a day as a therapy. The study observation group consisted of 32 men with balanoposthitis on the background of diabetes mellitus, for whom therapy Balanex cream gel was prescribed topically 2 times a day. The control group included 29 men with nonspecific balanoposthitis, for whom therapy by a combined cream (antibacterial + antifungal component) was used topically 2 times a day. Results and discussion. In all patients, the results of repeated microbiological examination were negative. The time of disappearance of the patient's disturbing symptoms ranged from 2 to 7 days, on average it was 3.2 ± 1.1 days, the median value was 3 days. At the same time, the presence of diabetes mellitus in the patient significantly prolonged the period of disappearance of symptoms to 3.9 days. The average value of this indicator was 3.0±0.6 vs. 3.9±1.6 vs. 3.0±0.8 days (p<0,001). Conclusions. Balanex cream gel significantly and comparably with the combined cream reduces the severity of symptoms that occur with balanoposthitis, including patients with diabetes mellitus.